SCHEMBL14606895

SCHEMBL14606895

CBc1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNc2nc(NC3CC3)c3ccccc3n2)CC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 17/20 0.56
▸ ADRA2A P08913 7/20 0.56
▸ MCHR1 Q99705 7/20 0.56
▸ AQP1 P29972 2/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ NPY1R P25929 1/20 0.56
▸ NPY2R P49146 1/20 0.56
▸ NPY4R P50391 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ SLC6A4 P31645 2/20 0.48
▸ APP P05067 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14606901 0.88 NPY5R (0.55) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796935 0.87 NPY5R (0.60) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796283 0.87 NPY5R (0.60) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796949 0.86 AQP1 (0.65) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796952 0.85 NPY5R (0.66) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL14606990 0.84 NPY5R (0.71) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL14606897 0.84 NPY5R (0.56) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796626 0.84 NPY5R (0.56) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL14606996 0.83 NPY5R (0.58) NPY5RADRA2AMCHR1AQP1ALDH1A1
SCHEMBL13796631 0.83 NPY5R (0.58) NPY5RADRA2AMCHR1AQP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide MCHR1, MCHR2, MC4R NPY5R 11/4885ADRA2A 131/4885MCHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback